HAEMOLYTIC OF NEWBORN DISEASE-RELATED RED BLOOD CELL ALLOANTIBODIES

Authors

  • Prasanthini Nahendran Programme of Biomedical Science, Centre for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia https://orcid.org/0000-0002-8283-8039
  • Siti Balkis Budin Programme of Biomedical Science, Centre for Diagnostic, Therapeutic and Investigation, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia
  • Nur Zakiah Mohd Saat Programme of Biomedical Science, Centre of Community Health, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia
  • Mohd Faeiz Yusop Blood Transfusion Unit, Pathology Department, Hospital Selayang, 68100, Batu Caves, Selangor, Malaysia
  • Tengku Norita Tengku Yazid Blood Transfusion Unit, Pathology Department, Hospital Selayang, 68100, Batu Caves, Selangor, Malaysia
  • Nur Najmi Mohamad Anuar Programme of Biomedical Science, Centre for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia https://orcid.org/0000-0001-6257-8316

DOI:

https://doi.org/10.11113/jurnalteknologi.v85.18550

Keywords:

Alloimmunisation, HDN, Alloantibodies, ABO incompatibility, hyperbilirubinemia, Phototherapy

Abstract

Red cell alloimmunisation in pregnancy may result in haemolytic disease of the foetus and newborn (HDN). During pregnancy, there are possibilities of the foetal antigen being exposed to the mother’s circulation, thereby leading to the production of antibodies. The immunoglobulin G (IgG) antibodies from the mother pass through the maternal surface placenta, which is then sensitised and obstructs the formation of foetal red blood cells (RBCs). This review discusses the presence of variance alloantibodies during pregnancy, as well as the consequences of HDN and its management. This review revealed that ABO incompatibility is the most common cause of alloimmunisation in pregnancy. The Rh system (anti-D and -E) are the most common alloantibodies found in pregnant women, followed by other alloantibodies such as Kell, Duffy, Kidd and MNSs. Hyperbilirunemia (increased bilirubin levels) is commonly seen in neonatal jaundice due to HDN and it is usually manageable using the phototherapy method. Nevertheless, the clinical significance of alloantibodies can cause complications such as anaemia, and in some extreme cases, kernicterus might require a blood exchange transfusion.

References

Altuntas, N., Yenicesu, I., Himmetoglu, Ö., Kulali, F., Kazanci, E., Unal, S., et al. 2013. The Risk Assessment Study for Hemolytic Disease of the Fetus and Newborn in a University Hospital in Turkey. Transfus Apher Sci. 48(3): 377-80.

Pitan, C., Syed, A., Murphy, W., Akinlabi, O., Finan, A. 2013. Anti-S Antibodies: An Unusual Cause of Haemolytic Disease of the Fetus and Newborn (HDFN). BMJ Case Rep. 2012-4.

Bi, S. H., Jiang, L. L., Dai, L. Y., Zheng,H., Zhang, J., Wang, L. L., et al. 2019. Rh-incompatible Hemolytic Disease of the Newborn in Hefei. World J Clin Cases. 7(20): 3202-7.

Agrawal, A., Hussain, K. S., Kumar, A. 2020. Minor Blood Group Incompatibility Due to Blood Groups Other than Rh(D) Leading to Hemolytic Disease of Fetus and Newborn: A Need for Routine Antibody Screening during Pregnancy. Intractable Rare Dis Res. 9(1): P1-5.

Kim, W. D., Lee, Y. H. 2006. A Fatal Case of Severe Hemolytic Disease of Newborn Associated with Anti-Jkb. J Korean Med Sci. 21(1): 151-4.

Sankaralingam, P., Jain, A., Bagga, R., Kumar, P., Marwaha, N. 2016. Red Cell Alloimmunization in RhD Positive Pregnant Women and Neonatal Outcome. Transfus Apher Sci. 55(1): 153-8. http://dx.doi.org/10.1016/j.transci.2016.06.002.

Raguz, M. J., Prce, Z., Bjelanovic, V., Bjelanovic, I., Dzida, S., Mabic, M. 2020. 20 Years of Follow-up Alloimmunization and Hemolytic Disease in Newborn: Has Anything Changed in the Field over the Years? Klin Padiatr. 232(6): 314-20.

Moinuddin, I., Fletcher, C., Millward, P. 2019. Prevalence and Specificity of Clinically Significant Red Cell Alloantibodies in Pregnant Women-A Study from a Tertiary Care Hospital in Southeast Michigan. J Blood Med. 10: 283-9.

Gupta, G., Balbuena Merle, R., Hendrickson, J. E., Tormey, C. A. 2020. Immunohematologic Aspects of Alloimmunization and Alloantibody Detection: A Focus on Pregnancy and Hemolytic Disease of the Fetus and Newborn. Transfus Apher Sci. 59(5): 102946. https://doi.org/10.1016/j.transci.2020.102946.

Kahar, M. 2018. Frequency of Red Cell Alloantibodies in Pregnant Females of Navsari District: An Experience that Favours Inclusion of Screening for Irregular Erythrocyte Antibody in Routine Antenatal Testing Profile. J Obstet Gynecol India. 68(4): 300-5.

Leonard, A., Hittson Boal, L., Pary, P., Mo, Y. D., Jacquot, C., Luban, N. L., et al. 2019. Identification of Red Blood Cell Antibodies in Maternal Breast Milk Implicated in Prolonged Hemolytic Disease of the Fetus and Newborn. Blood. 59(4): 1183-9.

Arora, S., Doda, V., Maria, A., Kotwal, U., Goyal, S. 2015. Maternal anti-M Induced Hemolytic Disease of Newborn Followed by Prolonged Anemia in Newborn Twins. Asian J Transfus Sci. 9(1): 98-101.

Kimball, C. 2019. ABO Incompatibility in the Newborn. J Neonatol. 33(1-4): 22-5.

Gupta, V., Sidhu, M., Shah, S. N. 2020. Hemolytic Disease of the Fetus and Newborn Due to Multiple Alloantibodies in Pregnancy. Asian J Transfus Sci. 14(1): 83-6.

Singh, B., Chaudhary, R., Katharia, R. 2020. Effect of Multiple Maternal Red Cell Alloantibodies on the Occurrence and Severity of Hemolytic Disease of the Fetus and Newborn. Transfus Apher Sci. May: 102958. https://doi.org/10.1016/j.transci.2020.102958.

Basu, S., Kaur, R., Kaur, G. 2011. Hemolytic Disease of the Fetus and Newborn: Current Trends and Perspectives. Asian J Transfus Sci. 5(1): 3-7.

Dean, L. 2005. The Causes of HDN and How to Minimize. In: Blood Groups and Red Cell Antigens. National Center for Biotechnology Information (US).

Dean, L. 2005. The Kell Blood Group. In: Blood Groups and Red Cell Antigens. National Center for Biotechnology Information (US).

Markham, K. B., Rossi, K. Q., Nagaraja, H. N., O’Shaughnessy, R. W. 2015. Hemolytic Disease of the Fetus and Newborn Due to Multiple Maternal Antibodies. Am J Obstet Gynecol. 213(1): 68.e1-68.e5. http://dx.doi.org/10.1016/j.ajog.2015.01.049.

Webb, J., Delaney, M. 2018. Red Blood Cell Alloimmunization in the Pregnant Patient. Transfus Med Rev. 32(4): 213-9. https://doi.org/10.1016/j.tmrv.2018.07.002.

Koelewijn, J. M., Slootweg, Y. M., Folman, C., van Kamp, I. L., Oepkes, D., de Haas, M. 2020. Diagnostic Value of Laboratory Monitoring to Predict Severe Hemolytic Disease of the Fetus and Newborn in non-D and non-K-alloimmunized Pregnancies. Transfusion. 60(2): 391-9.

Thakral, B., Agrawal, S. K., Dhawan, H. K., Saluja, K., Dutta, S., Marwaha, N. 2007. First Report from India of Haemolytic Disease of Newborn by anti-c and anti-E in Rh (D) Positive Mothers. Hematology. 12(5): 377-80.

Bao, R., Wang, S., Yang, Q. 2017. Clinical Study of the Relationship between Prenatal Antibody Titer and Hemolytic Disease of Newborn. Int J Clin Exp Med. 10(1): 1637-42.

Akanmu, A. S., Oyedeji, O. A., Adeyemo, T. A., Ogbenna, A. A. 2015. Estimating the Risk of ABO Hemolytic Disease of the Newborn in Lagos. J Blood Transfus. 2015: 1-5.

Rahimi-Levene, N., Chezar, J., Yahalom, V. 2020. Red Blood Cell Alloimmunization Prevalence and Hemolytic Disease of the Fetus and Newborn in Israel: A Retrospective Study. Transfusion. June: 1-7.

Xie, X., Fu, Q., Bao, Z., Zhang, Y., Zhou, D. 2020. Clinical Value of Different anti-D Immunoglobulin Strategies for Preventing Rh Hemolytic Disease of the Fetus and Newborn: A Network Meta-analysis. PLoS One. 15(3). http://dx.doi.org/10.1371/journal.pone.0230073.

Bhat, Y. R., Pavan Kumar, C. G. 2012. Morbidity of ABO Haemolytic Disease in the Newborn. Paediatr Int Child Health. 32(2): 93-6.

Yahya, E., Mona, K., Rola Azhir. 2020. Rh Blood Group Positive Newborn of Rh Blood Group Negative Parents, Why, and How? Al-Anbar Med J. 16(2): 10-2.

John, C., Triana, M., Sassan, G. 2020. Rh Incompability. Stat. Pearls Publ. 1.

Izetbegovic, S. 2013. Occurrence of ABO and RhD Incompatibility with Rh Negative Mothers. Mater Socio Medica. 25(4): 255.

Li, S., He, Z., Luo, Y., Ji, Y., Luo, G., Fang, Q., et al. 2020. Distribution of Maternal Red Cell Antibodies and the Risk of Severe Alloimmune Haemolytic Disease of the Foetus in a Chinese Population: A Cohort Study on Prenatal Management. BMC Pregnancy Childbirth. 20(1): 1-11.

Hall, V., Avulakunta, I. D. 2022. Hemolytic Diseases of the Newborn. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32491355.

Anshu, G., Shabanam, M., Sarbjeet, K., Roopali, S., Sujata, C., Bharat, S. 2016. Enigmatic Weak D Antigen: An Expression in a Tertiary Care Hospital of East Delhi. J Clin Diagnostic Res. 6.

Gariod, S., Brossard, Y., Poissonnier, M. H., Vuilliez, B., Deutsch, V., Jouk, P. S., et al. 2004. Kell Alloimmunization in Pregnancy. J Gynecol Obstet Biol la Reprod. 33(7): 637-48.

Mina, S., Bhardwaj, R., Gupta, S. 2017. Hemolytic Disease of Newborn: Can Think Beyond Rh (D) and ABO Incompatibilities. J Clin Neonatol. 6(1): 37.

Soumya, D. 2018. Hemolytic Disease of the Fetus and Newborn. In: The 5-Minute Pediatric Consult. 8th Edition. 426-7.

Usman, A. S. idu, Mustaffa, R., Ramli, N., Diggi, S. A. 2013. Hemolytic Disease of the Fetus and Newborn Caused by Anti-E. Asian J Transfus Sci. 7(1): 84-5.

McAdams, R. M., Dotzler, S. A., Winter, L. W.t, Kerecman, J. D. 2008. Severe Hemolytic Disease of the Newborn from Anti-e. J Perinatol. 28(3): 230-2.

Howard, H., Martlew, V., McFadyen, I., Clarke, C., Duguid, J., Bromilow, I., et al. 2015. Consequences for Fetus and Neonate of Maternal Red Cell Allo- immunisation. Arch Dis Child Fetal Neonatal Ed. 78(1): 62-7.

Kristin, S., Christopher. A. T., L. Baine. 2020. Methods of RBC Alloimmunization to ABO and Non-ABO Antigens, and Test Methodologies. In: Immunologic Concepts in Transfusion Medicine. 12-23.

Santiago, J. C., Ramos-Corpas, D., Oyonarte, S., Montoya, F. 2008. Current Clinical Management of Anti-Kell Alloimmunization in Pregnancy. Eur J Obstet Gynecol Reprod Biol. 136(2): 151-4.

Koumoutsea, E., Maciej, W., Garbowski, Gareth, S., Rory, Windrim Johannes, Keunen Edmond K., Tim, VanMieghem, Nadine, S. 2019. Is There a Role for Titre Monitoring in Kell Alloimmunized Pregnancies? The American Society of Hematology.

Connie, M. W., Beth, H. S. Kell and Kidd Blood Group Systems. 2013. In: Transfusion Medicine and Hemostasis (Second Edition). 163-6.

Joint United Kingdom Blood Transfusion. 2020. Prevention of Hemolytic Disease of the Fetus and Newborn (HDFN). In: Transfusion Handbook. 1-2.

Saul, S., J. MoiseJr. K. 2020. Haemolytic Disease of the Fetus and Newborn. In: Fetal Medicine (Third Edition). 484-96.

M. Westhoff C., E. Reid M. Rh., Kell, Duffy, and Kidd. 2007. Antigens and Antibodies. In: Blood Banking and Transfusion Medicine (Second Edition). 80-95.

Mattaloni, S. M., Arnoni, C., Céspedes, R., Nonaka. C., Boggione, C. T., Brajovich, M. E. L., et al. 2017. Clinical Significance of an Alloantibody against the Kell Blood Group Glycoprotein. Transfus Med Hemotherapy. 44(1): 53-7.

Erhabor, S., Alhaji, Y., Yakubu, Duffy. 2014. Red Cell Phenotypes among Pregnant Women in Sokoto, North Western Nigeria. J Blood Disord Transfus. 05(07).

Fatima, A. A. 2019. The Duffy Blood Group System. In: Human Blood Group Systems and Haemoglobinopathies. 120-59.

Goodrick, M. J., Hadley, A. G., Poole, G. 2013. Haemolytic Disease of the Fetus and Newborn Due to Anti-Fya and the Potential Clinical Value of Duffy Genotyping in Pregnancies at Risk. Transfus Med. 7(4): 301-4.

Michelle, L. E. 2020. Alloimmunization in Pregnancy. In: Immunologic Concepts in Transfusion Medicine. 149-65.

Hughes, L. H., Rossi, K. Q., Krugh, D. W., O’Shaughnessy, R. W. 2007. Management of Pregnancies Complicated by Anti-Fya Alloimmunization. Transfusion. 47(10): 1858-61.

Mittal, K., Sood, T., Bansal, N., Bedi, R. K., Kaur, P., Kaur, G. 2016. Clinical Significance of Rare Maternal Anti Jka Antibody. Indian J Hematol Blood Transfus. 32(4): 497-9.

Janis, R. H., Connie, M. W. Kell, Kx and Kidd Blood Group Systems. 2019. In: Transfusion Medicine and Hemostasis (Third Edition). 157-61.

Velasco Rodríguez, D., Pérez-Segura, G., Jiménez-Ubieto, A., Rodríguez, M. A., Montejano, L. 2014. Hemolytic Disease of the Newborn due to Anti-Jkb: Case Report and Review of the Literature. Indian J Hematol Blood Transfus. 30(2): 135-8.

Karagol, B. S., Zenciroglu, A., Okumus, N., Karadag, N., Dursun, A., Hakan, N. 2012. Hemolytic Disease of the Newborn Caused by Irregular Blood Subgroup (Kell, C, c, E, and e) Incompatibilities: Report of 106 Cases at a Tertiary-care Centre. Am J Perinatol. 29(6): 449-54.

Sánchez-Durán, M. Á., Higueras, M. T., Halajdian-Madrid, C,, Avilés García, M., Bernabeu-García, A., Maiz, N, et al. 2019. Management and Outcome of Pregnancies in Women with Red Cell Isoimmunization: A 15-year Observational Study from a Tertiary Care University Hospital. BMC Pregnancy Childbirth. 19(1): 1-8.

Ishida, A., Ohto, H., Yasuda, H., Negishi, Y., Tsuiki, H., Arakawa, T., et al. 2015. Anti-M Antibody Induced Prolonged Anemia Following Hemolytic Disease of the Newborn Due to Erythropoietic Suppression in 2 Siblings. J Pediatr Hematol Oncol. 37(6): e375–7.

Crispin, P., Sliwinski, K., Wilson, C., Lennard, S., DeSouza, M., Sethna, F. 2019. Cold Reacting anti-M Causing Delayed Hemolytic Disease of the Newborn. Transfusion. 59(12): 3575-9.

Yu, M., Graham, K., Pasalic, L., Alahakoon, T. I. 2019. Recurrent Fetal Hydrops with Maternal M Alloimmunisation: Not a Benign Condition. BMJ Case Rep. 12(7): 1-4.

Karim, F., Moiz, B., Kamran, N. 2015. Risk of Maternal Alloimmunization in Southern Pakistan - A Study in a Cohort of 1000 Pregnant Women. Transfus Apher Sci. 52(1): 99-102. Available from: http://dx.doi.org/10.1016/j.transci.2014.12.002.

Yasuda, H., Ohto, H., Nollet, K. E., Kawabata, K., Saito, S., Yagi, Y., et al. 2014. Hemolytic Disease of the Fetus and Newborn with Late-onset Anemia due to Anti-M: A Case Report and Review of the Japanese Literature. Transfus Med Rev. 28(1): 1-6. Available from: http://dx.doi.org/10.1016/j.tmrv.2013.10.002.

E. Reid, M., M. Westhoff, C. 2007. Other Blood Group Antigens and Antibodies. In: Blood Banking and Transfusion Medicine (Second Edition). 96-111.

Hyland, C. A., O’Brien, H., Flower, R. L., Gardener, G. J. 2020. Non-invasive Prenatal Testing for Management of Haemolytic Disease of the Fetus and Newborn Induced by Maternal Alloimmunisation. Transfus Apher Sci. 59(5): 102947. Available from: https://doi.org/10.1016/j.transci.2020.102947.

Yousuf, R., Abdul Aziz, S., Yusof, N., Leong, C. F. 2012. Hemolytic Disease of the Fetus and Newborn Caused by Anti-D and Anti-S Alloantibodies: A Case Report. J Med Case Rep. 6: 6-8.

Derek, N. 2013. Handbook of Transfusion Medicine. 5th Edition. TSO.

Children’s Hospital of Philadelphia. Hemolytic Disease of the Newborn. 2021. https://www.chop.edu/conditions-diseases/hemolytic-disease-newborn.

Lindenburg, I. T. M., Van Kamp, I. L., Oepkes, D. 2014. Intrauterine Blood Transfusion: Current Indications and Associated Risks. Fetal Diagn Ther. 36(4): 263-71.

Al-Riyami, A. Z. Al-Salmani, M., Al-Hashami, S. N., Al-Mahrooqi, S., Al-Marhoobi, A., Al-Hinai, S., et al. 2018. Intrauterine Fetal Blood Transfusion: Descriptive Study of the First Four Years’ Experience in Oman. Sultan Qaboos Univ Med J. 18(1): e34-42.

Sawyer, L. T., Chiles, P. D. 2018. Phototherapy for Jaundice. Medscape. https://emedicine.medscape.com/article/1894477-overview.

McAdams, R. M. . 2016. Delayed Cord Clamping in Red Blood Cell Alloimmunization: Safe, Effective, and Free? Transl Pediatr. 5(2): 100-3.

Mandal, S., Malhotra, S., Negi, G., Tiwari, A., Mitra, S., Basu, S., et al. 2020. Severe Hemolytic Disease of the Fetus and Newborn due to Anti-E and Anti-Jka. Immunohematology. 36(2): 60-3.

Wagle, S., Deshpande, P. G. 2020. Hemolytic Disease of the Newborn Treatment & Management. Medscape. https://emedicine.medscape.com/article/974349-treatment.

MedlinePlus (Internet). Bethesda (MD): National Library of Medicine (US); (updated September 11; cited 2021). Hemolytic Disease of the Newborn. https://medlineplus.gov/ency/article/001298.htm.

Ministry of Health Malaysia. 2022. Perinatal Care Manual. 4th Edition.

ARUP Laboratories; (updated March; cited 2022). Alloimmune Hemolytic Disease of the Fetus and Newborn. Retrieved from https://ltd.aruplab.com/api/ltd/pdf/102.

Downloads

Published

2022-12-02

How to Cite

Nahendran, P. ., Budin, S. B., Mohd Saat, . N. Z. ., Yusop, M. F. . ., Tengku Yazid, T. N., & Mohamad Anuar, N. N. (2022). HAEMOLYTIC OF NEWBORN DISEASE-RELATED RED BLOOD CELL ALLOANTIBODIES. Jurnal Teknologi, 85(1), 1-9. https://doi.org/10.11113/jurnalteknologi.v85.18550

Issue

Section

Science and Engineering